Skip Navigation LinksHome > December 2012 - Volume 60 - Issue 8 > IL-33: A Potential Therapeutic Target in Autoimmune Disease...
Journal of Investigative Medicine:
doi: 10.231/JIM.0b013e31826d8fcb
Review Article

IL-33: A Potential Therapeutic Target in Autoimmune Diseases

Wang, Song MM*†‡; Ding, Lei MM†‡; Liu, Shan-Shan MM†‡; Wang, Chao MD†‡; Leng, Rui-Xue MD†‡; Chen, Gui-Mei MD†‡; Fan, Yin-Guang MD†‡; Pan, Hai-Feng MD†‡; Ye, Dong-Qing MD, PhD†‡

Collapse Box


Abstract: Interleukin 33 (IL-33) is a newly described member of the IL-1 superfamily of cytokines. Through activation of the ST2 receptor, which is widely expressed particularly by helper T 2 cells and mast cells, IL-33 is involved in T-cell–mediated immune responses. Many previous studies have demonstrated that IL-33 may have a pleiotropic function in different diseases, and it could represent a novel target for the treatment of a range of diseases. Recent works have explored the role of IL-33 in chronic autoimmune diseases, such as systemic sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus. These results indicate that IL-33 may contribute to the pathogenesis of chronic autoimmune diseases. Hence, in this review, we discuss the biological features of IL-33 and summarize recent advances on the role of IL-33 in the pathogenesis and treatment of autoimmune diseases.

© 2012 American Federation for Medical Research


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.